The question of whether the striking antidepressant effects of psilocybin reported in randomised trials can be reproduced in everyday care remains largely unanswered. This is because those trials enrol highly selected patients, withdraw concomitant medication and deliver treatment under tightly standardised protocols. In this issue, Jungwirth et al. provide one of the first responses from...
In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments. While access remains limited, recent initiatives in Switzerland, Germany, and the Czech Republic illustrate growing momentum toward regulated use. We examine the debate surrounding psychedelics as pharmacological agents versus...
Psychedelic-assisted psychotherapy: hope and dilemmaPsychedelic-assisted psychotherapy is an emerging therapeutic approach that combines the use of psychedelics (a subclass of hallucinogenic drugs) and psychotherapy for the treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.Compared with current treatments for depression, psychedelic-assisted psychotherapy has...